ABSTRACT
There are few studies about the treatment of metastatic castration-resistant prostate cancer (mCRPC) with darolutamide. This paper reports a case that an 83-year-old patient complained of dysuria. His initial diagnosis was metastatic hormone sensitive prostate cancer(mHSPC). Androgen deprivation therapy (ADT) plus bicalutamide was performed. Re-examination of bone scan after half a year revealed that there were more than two new bone metastases, which was considered entering mCRPC. Due to the patient’s advanced age, post medical history of epilepsy, type 2 diabetes and cardiac radiofrequency ablation, long-term use of phenobarbital and repaglinide, the therapy was changed to ADT plus darolutamide to avoid drug contraindications. Re-examination of bone scan after 10 months revealed decreased metabolism in some metastases, and tPSA declined continuously.
ABSTRACT
Prostate cancer is one of the most common cancers threatening the health of males. The incidence of prostate cancer in China is on the rise. Non-metastatic castration-resistant stage is a special disease stage during the progression of prostate cancer, early identification of nmCRPC and prompt intervention can help delay disease progression and prolong patient survival. In recent years, many studies demonstrated the efficacy of novel androgen receptor inhibitors such as apalutamide, in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This article reviews the recent progress of novel androgen receptor inhibitors for nmCRPC.
ABSTRACT
In the past two decades, the development and marketing of several novel androgen receptor inhibitors added new options for the treatment of prostate cancer and extended the understanding of the management of prostate cancer. Brief review of the development history and the key aspects of these inhibitors will be conducive to individualised therapy, and further improve patient survival and other clinical benefits.